CJC-1295 + Ipamorelin Blend

Also known as: CJC/Ipa, GH Stack, Gold Standard GH Blend, Mod GRF 1-29 + Ipamorelin, CJC-1295 no DAC + Ipamorelin

Evidence: Preclinical

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

Overview

Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin, sold as 10 mg (5 mg each); the two act on separate GH-releasing receptors, and no study has tested the pair.

Both catalog vendors sell this as CJC-1295 without DAC, also called Mod GRF 1-29, mixed 5 mg/5 mg with ipamorelin. That is a different molecule from CJC-1295 with DAC, which lasts days; Mod GRF 1-29 has no published study of its own, and its D-Ala2 substitution only extends the half-time of GHRH(1-29) to about 7 min in men (Soule 1994). Ipamorelin released GH without raising cortisol in swine (Raun 1998) and has one human PK study and one negative phase 2 trial in postoperative ileus (Beck 2014). GHRH and GHRP-class peptides act synergistically on GH release in men (Bowers 1990), the rationale for pairing them, but no study has tested this blend. FDA lists ipamorelin in category 2 for 503B outsourcing and CJC-1295 in the withdrawn-nomination table of its compounding safety-risk page.

Benefits

GH pulse after IV ipamorelin (human PK study); GH release by Mod GRF 1-29 inferred from related GHRH analogs; body-composition, sleep and recovery claims untested for the blend or either component

Dosing reference

Research dose: 200 to 500 mcg of blend per injection (100 to 250 mcg of each at the 5 mg/5 mg ratio), 1 to 3x daily: vendor/community range, no published human dose of the blend or of Mod GRF 1-29
Range: 200 to 500 mcg, 1-3x daily
Reconstitution: 2 mL bacteriostatic water
Common vial sizes: 10 mg

Subcutaneous in community use, usually fasted or at bedtime; neither timing has been compared in a study of this blend. Human ipamorelin doses were IV and weight-based: 4 to 140 nmol/kg over 15 min (about 3 to 100 mcg/kg) in the PK study and 0.03 mg/kg twice daily in the ileus trial. No human dose of Mod GRF 1-29 has been published. The 5 days on, 2 days off pattern is community convention.

Mechanism

Proposed, from component and class studies. Mod GRF 1-29 is a tetrasubstituted GHRH(1-29) analog that binds the GHRH receptor on pituitary somatotrophs; its D-Ala2 change blocks cleavage between residues 2 and 3 in plasma, but its activity has not been measured directly. Ipamorelin is a pentapeptide agonist of the ghrelin receptor (GHS-R1a); in swine it released GH with GHRP-6-like potency without raising ACTH or cortisol (Raun 1998). In men, GHRH(1-44) given with GHRP-6 produced a GH response larger than either alone (Bowers 1990), which is the basis for pairing the two receptor pathways. The older claims of 2 to 5 times greater GH release and of a 'cleanest' stack have no published source for this blend.

Evidence

Preclinical: animal or in vitro data only

D-Ala2 substitution, one of Mod GRF 1-29's four changes, raised the plasma half-time of GHRH(1-29) from 4.3 to 6.7 min in 10 normal men (Soule et al., 1994)
Ipamorelin released GH with GHRP-6-like potency but without ACTH or cortisol rise in swine (Raun et al., 1998)
IV ipamorelin in 40 healthy men: dose-proportional PK, 2 h terminal half-life, single GH peak at 40 min (Gobburu et al., 1999)
Phase 2 RCT of IV ipamorelin in postoperative ileus (n=114): well tolerated, no efficacy difference from placebo (Beck et al., 2014)
Human-trial status: no study has tested the blend as sold, and none has tested Mod GRF 1-29 itself. GHRH(1-44) plus GHRP-6 was synergistic for GH release in men (Bowers et al., 1990); CJC-1295 with DAC, a different molecule, raised GH and IGF-1 for days in phase 1/2 trials (Teichman et al., 2006)

References

Side effects

No human safety study of the blend or of Mod GRF 1-29 has been published. IV ipamorelin was well tolerated in a 114-patient phase 2 trial (Beck 2014). Commonly reported by users (anecdotal): injection-site reactions, flushing, head rush, water retention and joint aches; reduced insulin sensitivity and carpal tunnel symptoms are reported with sustained GH elevation. Ipamorelin is in category 2 of FDA's 503B interim policy (added 2023-09-29), and ipamorelin and CJC-1295 are in the withdrawn-nomination table for 503A, as of 2026-04-22: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. FDA cites serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.

Storage

Storage: Refrigerate 2-8°C (36-46°F)
Lyophilized: 2+ years at room temp, 3+ years refrigerated
Reconstituted: 28-30 days refrigerated

Pharmacology

Half-life: Mod GRF 1-29 not measured; D-Ala2-GHRH(1-29) ~6.7 min (human, IV). Ipamorelin ~2 h terminal (human, IV). The ~30 min figure for Mod GRF is community lore
Bioavailability: Not measured for either component by subcutaneous injection; human ipamorelin data are IV. No data for the blend